Van Berkel T J, De Rijke Y B, Kruijt J K
Division of Biopharmaceutics, University of Leiden, The Netherlands.
J Biol Chem. 1991 Feb 5;266(4):2282-9.
Human low density lipoprotein was oxidized (Ox-LDL) by exposure to 5 microM Cu2+ and its fate in vivo was compared to acetylated low density lipoprotein (Ac-LDL). Ox-LDL, when injected into rats, is rapidly removed from the blood circulation by the liver, similarly as Ac-LDL. A separation of rat liver cells into parenchymal, endothelial, and Kupffer cells at 10 min after injection of Ox-LDL or Ac-LDL indicated that the Kupffer cell uptake of Ox-LDL is 6.8-fold higher than for Ac-LDL, leading to Kupffer cells as the main liver site for Ox-LDL uptake. In vitro studies with isolated liver cells indicated that saturable high affinity sites for Ox-LDL were present on both endothelial and Kupffer cells, whereby the capacity of Kupffer cells to degrade Ox-LDL is 6-fold higher than for endothelial cells. Competition studies showed that unlabeled Ox-LDL competed as efficiently (90%) as unlabeled Ac-LDL with the cell association and degradation of 125I-labeled Ac-LDL by endothelial and Kupffer cells. However, unlabeled Ac-LDL competed only partially (20-30%) with the cell association and degradation of 125I-labeled Ox-LDL by Kupffer cells, while unlabeled Ox-LDL or polyinosinic acid competed for 70-80%. It is concluded that the liver contains, in addition to the scavenger (Ac-LDL) receptor which interacts efficiently with both Ac-LDL and Ox-LDL and which is concentrated on endothelial cells, an additional specific Ox-LDL receptor which is highly concentrated on Kupffer cells. In vivo the specific Ox-LDL recognition site on Kupffer cells will form the major protection system against the occurrence of the atherogenic Ox-LDL particles in the blood.
人低密度脂蛋白通过暴露于5微摩尔/升的Cu2+被氧化(氧化型低密度脂蛋白,Ox-LDL),并将其在体内的情况与乙酰化低密度脂蛋白(Ac-LDL)进行比较。当将Ox-LDL注射到大鼠体内时,它会像Ac-LDL一样迅速从血液循环中被肝脏清除。在注射Ox-LDL或Ac-LDL后10分钟,将大鼠肝细胞分离为实质细胞、内皮细胞和库普弗细胞,结果表明库普弗细胞对Ox-LDL的摄取比Ac-LDL高6.8倍,这使得库普弗细胞成为肝脏摄取Ox-LDL的主要部位。对分离的肝细胞进行的体外研究表明,内皮细胞和库普弗细胞上都存在Ox-LDL的可饱和高亲和力位点,其中库普弗细胞降解Ox-LDL的能力比内皮细胞高6倍。竞争研究表明,未标记的Ox-LDL与未标记的Ac-LDL一样有效地(90%)竞争内皮细胞和库普弗细胞对125I标记的Ac-LDL的细胞结合和降解。然而,未标记的Ac-LDL仅部分(20 - 30%)竞争库普弗细胞对125I标记的Ox-LDL的细胞结合和降解,而未标记的Ox-LDL或聚肌苷酸的竞争率为70 - 80%。得出的结论是,肝脏中除了存在与Ac-LDL和Ox-LDL都能有效相互作用且集中在内皮细胞上的清道夫(Ac-LDL)受体外,还存在一种高度集中在库普弗细胞上的额外的特异性Ox-LDL受体。在体内,库普弗细胞上的特异性Ox-LDL识别位点将形成针对血液中致动脉粥样硬化的Ox-LDL颗粒出现的主要保护系统。